CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates
CRSPCRISPR Therapeutics(CRSP) Zacks Investment Research·2024-05-09 06:11

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of 1.43pershareversustheZacksConsensusEstimateofalossof1.43 per share versus the Zacks Consensus Estimate of a loss of 1.63. This compares to loss of 0.67pershareayearago.Thesefiguresareadjustedfornon−recurringitems.Thisquarterlyreportrepresentsanearningssurpriseof12.270.67 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 12.27%. A quarter ago, it was expected that this company would post a loss of 0.40 per share when it actually produced earnings of $1.10, delivering a surprise of 375%. Over the last four quarters, the company has ...